OverviewSuggest Edit

Protalex is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases. The Company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy and pemphigus. Its lead product candidate is PRTX-100, a formulation of a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide.
HQFlorham Park, NJ, US

Latest Updates

Employees (est.) (Feb 2019)2(-33%)
Revenue (FY, 2018)$0
Share Price (Jul 2021)$0
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Protalex

Arnold Kling

Arnold Kling

Director, President
William Gannon

William Gannon

Chief Medical Officer
Show more

Protalex Office Locations

Protalex has an office in Florham Park
Florham Park, NJ, US (HQ)
131 Columbia Turnpike
Show all (1)

Protalex Financials and Metrics

Protalex Revenue


Net income (Q1, 2019)


EBIT (Q1, 2019)


Market capitalization (15-Jul-2021)


Closing stock price (15-Jul-2021)


Cash (31-Aug-2018)



Protalex's current market capitalization is $615.2 k.
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense


R&D expense


Operating expense total

USDQ1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019


General and administrative expense


R&D expense


Operating expense total

USDQ1, 2012

Financial Leverage

-3.8 x
Show all financial metrics

Protalex Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Protalex Online and Social Media Presence

Embed Graph

Protalex Blogs

Protalex Announces Data from Phase 1b Trial of PRTX-100 in Patients with Immune Thrombocytopenia Presented at the European Hematology Association 23rd Annual Meeting

FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that data highlighting results from its European Phase 1b open-label, dose-escalation study of PRTX-100 in adult patients with persistent/chron…

Protalex Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in a Mouse Model of Myasthenia Gravis

Findings Support Advancement of PRTX-100 into its Third Clinical Indication FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced preliminary findings that its lead drug candidate…

Protalex Frequently Asked Questions

  • When was Protalex founded?

    Protalex was founded in 1999.

  • Who are Protalex key executives?

    Protalex's key executives are Arnold Kling and William Gannon.

  • How many employees does Protalex have?

    Protalex has 2 employees.

  • Who are Protalex competitors?

    Competitors of Protalex include Aerin Medical, Evox Therapeutics and EnteroBiotix.

  • Where is Protalex headquarters?

    Protalex headquarters is located at 131 Columbia Turnpike, Florham Park.

  • Where are Protalex offices?

    Protalex has an office in Florham Park.

  • How many offices does Protalex have?

    Protalex has 1 office.